Pre-made Modakafusp benchmark antibody ( Whole mAb Fusion, anti-ADPRC therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-352
Pre-Made Modakafusp biosimilar, Whole mAb Fusion: Anti-ADPRC therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Modakafusp alfa (formerly TAK 573 or TEV 48573) is a CD38 targeted antibody (IgG4) fused with attenuated interferon alpha (IFN-α), being developed by Takeda, through its wholly-owned subsidiary Millennium Pharmaceuticals, for the treatment of multiple myeloma and solid tumours.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Modakafusp biosimilar, Whole mAb Fusion: Anti-ADPRC therapeutic antibody|
|Format||Whole mAb Fusion|
|Highest_Clin_Trial (Jan '20)||Phase-I/II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Multiple myeloma|